𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Assessment of cardiotoxicity with cardiac biomarkers in cancer patients

✍ Scribed by D. Cardinale; C.M. Cipolla

Publisher
Urban and Vogel
Year
2011
Tongue
German
Weight
433 KB
Volume
36
Category
Article
ISSN
0340-9937

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

P067 Monitoring of cardiotoxicity in hem
P067 Monitoring of cardiotoxicity in hematooncology with cardiac biomarkers, echocardiography and electrocardiography
✍ J.M. Horacek; R. Pudil; M. Tichy; L. Jebavy; P. Zak; L. Slovacek πŸ“‚ Article πŸ“… 2007 πŸ› Elsevier Science 🌐 English βš– 52 KB

monosomy 8; 3 (25%) patients did not have metaphases and 3 (25%) had a normal karyotype. PCR analyses was done in one Ph+ and one Ph patient, and showed in both BCR/ABL rearrangement with p190 expression. One of bilineal leukemias showed trisomy 4, and other del(8)q(22). Five (42%) patients received

Biomarkers of depression in cancer patie
Biomarkers of depression in cancer patients
✍ Christian Friedrich Jehn; Dagmar Kuehnhardt; Andrea Bartholomae; Sebastian Pfeif πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 192 KB
Cardioprotection with ICRF-187 (Cardioxa
Cardioprotection with ICRF-187 (Cardioxane) in patients with advanced breast cancer having cardiac risk factors for doxorubicin cardiotoxicity, treated with the FDC regimen
✍ Svetislav JeliΔ‡; SiniΕ‘a RaduloviΔ‡; Zora NeΕ‘koviΔ‡-KonstantinoviΔ‡; Miroslav Kreači πŸ“‚ Article πŸ“… 1995 πŸ› Springer-Verlag 🌐 English βš– 743 KB

A study of cardioprotection with ICRF-187 (Cardioxane, Eurocetus) has been performed in 35 patients with metastatic breast cancer treated with the FDC regimen (5-fluorouracil 500 mg/m 2 i.v., day 1; doxorubicin 50 mg/m 2 i.v., day 1; cyclophosphamide 500 mg/ m 2 i.v., day 1). All patients had one or